It has been hypothesized that metalloproteinases, and particularly MMP3, could a have a role in degrading anti–tumor necrosis factor drugs, leading to treatment failure in patients with inflammatory bowel disease (IBD).
Activated metalloproteinases degrade both matrix and nonmatrix proteins, and play a key role in wound healing, tissue repair, and response to injury. When dysregulated, they can also have a role in the progression of inflammatory diseases and malignancies.
It has been hypothesized that these metalloproteinases, and particularly MMP3, could a have a role in degrading anti—tumor necrosis factor (anti-TNF) drugs, leading to anti-TNF failure in patients with inflammatory bowel disease (IBD).
Now, research presented at the 14th Congress of the European Crohn’s and Colitis Organisation finds that, after induction with infliximab, high MMP3 levels predicted a loss of response among patients with IBD over the coming 12 months.
In the study, the investigators retrospectively reviewed the data of 73 patients with IBD, 37 of whom had ulcerative colitis and 36 of whom had Crohn disease. Among the 73 patients, 37 had responded to anti-TNF therapy with infliximab after 52 weeks, and 36 had not responded.
All patients had their MMP3 tested at baseline, after induction, and again at 1 year. Trough levels and antidrug antibodies (ADAs) were also recorded at 1 year. The investigators also sampled the MMP3 levels of 28 healthy volunteers as controls.
They found that, between responders and nonresponders to infliximab, serum levels at baseline were not significantly different. However, after induction, responders had levels of 8.68 ng/ml while nonresponders had levels of 25.7 ng/ml (P <.001). At 12 months, these values were 11.63 ng/ml and 29.72 ng/ml, respectively (P <.001).
Furthermore, among nonresponders with low trough levels, those who had high ADA levels and those who had no ADAs had similar MMP3 levels (32.01 and 24.56, respectively, P = .1), and there was a significant negative correlation between MMP3 levels and trough levels at 1 year in the overall population.
According to the authors, high MMP3 levels post-induction predict loss of response over the next year, and patients who are nonresponders to infliximab, regardless of ADAs, demonstrate high MMP3 levels.
Reference
Barberio B, D’Inca R, Facchin S, et al. Mechanisms of infliximab failure: the predictive role of MMP3. Presented at the 14th Congress of the European Crohn’s and Colitis Organisation; March 6-9, 2019; Copenhagen, Denmark. Abstract P650.
Review: Product Attributes Relevant to Injection-Site Pain, Adalimumab Treatment
May 4th 2024A review article summarizes the product attributes of reference and biosimilar adalimumab products, such as formulation with or without citrate, delivery volume, and needle gauge, relevant to patients’ experience of injection-site pain.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
Biosimilars Gastroenterology Roundup for January 2024—Podcast Edition
February 4th 2024On this episode of Not So Different, we reminisce on all the major gastroenterology news from January, which brought several reports quantifying how the gastroenterology biosimilar market is progressing and marked the 1-year anniversary of adalimumab biosimilar competition in the US.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.